BG
FATE icon

Bellevue Group’s Fate Therapeutics FATE Stock Holding History

Bellevue Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,839,779
Closed -$7.99M – 155
2024
Q4 		$7.99M Hold
4,839,779
– – 0.15% 85
2024
Q3 		$16.9M Hold
4,839,779
– – 0.27% 77
2024
Q2 		$15.9M Hold
4,839,779
– – 0.26% 85
2024
Q1 		$35.5M Sell
4,839,779
-11,800
-0.2% -$73K 0.54% 59
2023
Q4 		$18.1M Hold
4,851,579
– – 0.28% 78
2023
Q3 		$10.3M Sell
4,851,579
-4,200
-0.1% -$13.9K 0.17% 90
2023
Q2 		$23.1M Hold
4,855,779
– – 0.33% 69
2023
Q1 		$27.7M Sell
4,855,779
-5,500
-0.1% -$33.2K 0.4% 66
2022
Q4 		$49.1M Buy
4,861,279
+1,115,193
+30% +$20.9M 0.65% 51
2022
Q3 		$84M Buy
3,746,086
+196,000
+6% +$5.66M 1.2% 26
2022
Q2 		$88M Sell
3,550,086
-26,400
-0.7% -$728K 1.24% 23
2022
Q1 		$139M Sell
3,576,486
-199,250
-5% -$7.72M 1.61% 15
2021
Q4 		$221M Buy
3,775,736
+537,700
+17% +$30.5M 2.28% 8
2021
Q3 		$192M Buy
3,238,036
+624,500
+24% +$49M 1.95% 10
2021
Q2 		$227M Buy
2,613,536
+404,200
+18% +$32.6M 2.21% 9
2021
Q1 		$182M Buy
2,209,336
+101,836
+5% +$9.76M 1.93% 11
2020
Q4 		$192M Sell
2,107,500
-110,000
-5% -$6.83M 2.19% 9
2020
Q3 		$88.6M Buy
2,217,500
+256,100
+13% +$8.94M 1.22% 23
2020
Q2 		$67.3M Buy
1,961,400
+398,200
+25% +$11.9M 0.95% 27
2020
Q1 		$34.7M Buy
1,563,200
+1,480,400
+1,788% +$37.4M 0.67% 42
2019
Q4 		$1.62M Buy
82,800
+22,700
+38% +$360K 0.03% 136
2019
Q3 		$933K Buy
60,100
+1,100
+2% +$21.1K 0.02% 147
2019
Q2 		$1.2M Buy
+59,000
New +$1.06M 0.02% 139

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Bellevue Group's FATE Position: Q1 2025 in Review

Bellevue Group sold out of Fate Therapeutics (FATE) in Q1 2025, closing a stake of 4,839,779 shares — an estimated $7.99M sold.

Bellevue Group first reported a position in FATE in Q2 2019 and held it in 23 quarters. The position peaked at $227M in Q2 2021. 132 funds tracked by Wall St. Rank hold FATE as of Q1 2025.

  • Bellevue Group reported no remaining Fate Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bellevue Group sold 4,839,779 Fate Therapeutics shares in Q1 2025, an estimated $7.99M.
  • Bellevue Group first reported a position in Fate Therapeutics in Q2 2019 and held it in 23 quarters.
  • Bellevue Group's Fate Therapeutics position peaked at $227M in Q2 2021.
  • 132 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2025.

Based on Bellevue Group's 13F filing for Q1 2025, filed 14 May 2025.